Basic Information
| LncRNA/CircRNA Name | CHRF |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, other |
| Sample | LAD tissues and cell lines (SPC-A1, NCI-H441 and NCI-H1975) |
| Expression Pattern | up-regulated |
| Function Description | Patients exhibiting upregulated CHRF also demonstrated advanced Tumor-Node-Metastasis stage, lymph node metastasis and larger tumor size compared with those exhibiting downregulated CHRF. Results of Cox proportional hazards regression analysis suggested that highly-expressed CHRF may be regarded as an independent prognostic factor of prognosis. In addition, loss-of-function assays indicated that downregulation of CHRF suppressed cell proliferation, migration and invasion, and induced cell cycle arrest and apoptosis. Western blotting revealed that the phosphoinositide-3-kinase/Akt signaling pathway activity is reduced in lung adenocarcinoma following the knockdown of CHRF. |
| Pubmed ID | 30333887 |
| Year | 2018 |
| Title | Long Non-Coding RNA, CHRF, Predicts Poor Prognosis of Lung Adenocarcinoma and Promotes Cell Proliferation and Migration |
External Links
| Links for CHRF | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |